Correlation Between Bristol-Myers Squibb and Novo Nordisk

Can any of the company-specific risk be diversified away by investing in both Bristol-Myers Squibb and Novo Nordisk at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bristol-Myers Squibb and Novo Nordisk into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Bristol Myers Squibb and Novo Nordisk AS, you can compare the effects of market volatilities on Bristol-Myers Squibb and Novo Nordisk and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bristol-Myers Squibb with a short position of Novo Nordisk. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bristol-Myers Squibb and Novo Nordisk.

Diversification Opportunities for Bristol-Myers Squibb and Novo Nordisk

-0.75

Correlation Coefficient

Bristol-Myers Squibb  Novo Nordisk

Pay attention - limited upside

The 3 months correlation between Bristol-Myers and Novo is -0.75. Overlapping area represents the amount of risk that can be diversified away by holding Bristol Myers Squibb and Novo Nordisk AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Novo Nordisk AS and Bristol-Myers Squibb is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bristol Myers Squibb are associated (or correlated) with Novo Nordisk. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Novo Nordisk AS has no effect on the direction of Bristol-Myers Squibb i.e., Bristol-Myers Squibb and Novo Nordisk go up and down completely randomly.

Pair Corralation between Bristol-Myers Squibb and Novo Nordisk

Assuming the 90 days horizon Bristol Myers Squibb is expected to generate 1.37 times more return on investment than Novo Nordisk. However, Bristol-Myers Squibb is 1.37 times more volatile than Novo Nordisk AS. It trades about 0.1 of its potential returns per unit of risk. Novo Nordisk AS is currently generating about -0.1 per unit of risk. If you would invest  80,112  in Bristol Myers Squibb on September 5, 2024 and sell it today you would earn a total of  15,443  from holding Bristol Myers Squibb or generate 19.28% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	96.88%
Values	Daily Returns

Bristol Myers Squibb  vs.  Novo Nordisk AS

Bristol Myers Squibb

Risk-Adjusted Performance

7 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Bristol Myers Squibb are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Even with relatively fragile primary indicators, Bristol-Myers Squibb reported solid returns over the last few months and may actually be approaching a breakup point.

Novo Nordisk AS

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Novo Nordisk AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Pair Trading with Bristol-Myers Squibb and Novo Nordisk

The main advantage of trading using opposite Bristol-Myers Squibb and Novo Nordisk positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bristol-Myers Squibb position performs unexpectedly, Novo Nordisk can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will offset losses from the drop in Novo Nordisk's long position.

The idea behind Bristol Myers Squibb and Novo Nordisk AS pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.